Research focus

Personalized, precision pediatric oncology using up to date theranostic approaches in order to increase survival and decrease long term morbidity and sequelae from the disease and necessary therapies.

Rational incorporation of new anticancer drugs into earlier lines of treatment based on comprehensive DNA, RNA and proteomic analyses of the tumor and the patient as the host.

Establishment of functional regional model for long term follow up with transition of care from pediatric to adult services as the platform to study long term toxicities, risk factors and possible ways to decrease the treatment burden.

Research objectives

  • Personalized precision pediatric oncology based on comprehensive assessment of the tumor and the host.
  • Decreasing the disease and treatment related morbidity and mortality while studying long term survivors and running juvenile animal studies for new anticancer medicines.
  • CSF proteomic project for children with brain tumors and leukemia and NHL. Analysis of possible biomarkers.

Main partners

  • Medical University of Vienna, Vienna, Austria
  • Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA
  • AP-HM, Marseille, France

Technological equipment

  • Mass Spectrometry - CSF proteomic analyzes
  • Phosphoproteomic Facility - phosphoproteomic analyzes
  • High-Performance Liquid Chromatography – sample analyzes

Offered services and expertise

  • Unique and well characterized population of young adults - former pediatric oncology patients who are in risk of late toxicity from the disease and the treatment and who should be looked after and further studied in many areas, mainly cardiology, neurology, endocrinology, pulmonology.
  • Established cooperation with international pediatric oncology centers in Europe and the US.

Top publications

  • THOMPSON, E.M., HIELSCHER, T., BOUFFET, E., REMKE, M., et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology. 2016 [Epub ahead of print].
  • MORRISSY, A. S., GARZIA, L., SHIH, D. J. H., ZUYDERDUYN, S., et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016, 529(7586), 351-357.
  • NERADIL, J., PAVLASOVA, G., SRAMEK, M. KYR, M., et al. DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: The same outcome of treatment with different doses in sensitive cell lines. Oncology Reports. 2015, 33(5), 2169-2175.
  • NORTHCOTT, P. A., LEE, C., ZICHNER, T., STUETZ, A. M., et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014, 511(7510), 428-434.
  • ZAPLETALOVA, D., N. ANDRE, L. DEAK, M. KYR, et al. Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience. Oncology. 2012, 82(5), 249-260.

Other selected results

Establishment of the functional model of national and international cooperation enabling access to full range of personalized precision diagnostics for children with cancer and designation of international pediatric oncology study group around Brno – CEPOETA.org which in cooperation with CZECRIN is the platform to further study personalized, precision pediatric oncology.

Team members

  • prof. MUDr. Jaroslav Štěrba, Ph.D.
  • Mgr. Blanka Jančeková, Ph.D.
  • prof. PharmDr. Petr Babula, Ph.D.
  • MUDr. Viera Bajčiová, CSc.
  • Ing. Veronika Balcarová
  • MUDr. Dáša Černá
  • Bc. Lucie Faberová, MSc
  • Mgr. Jitka Glossová
  • Mgr. Marta Holíková
  • prof. MUDr. Hana Hrstková, CSc.
  • Bc. Martina Indrová, DiS.
  • MUDr. Tomáš Kepák
  • Mgr. Katarína Kostolanská
  • PharmDr. Šárka Kozáková, MBA
  • MUDr. Michal Kýr, Ph.D.
  • prof. MUDr. Ondřej Ludka, Ph.D.
  • Ing. Tomáš Machulka
  • MUDr. Pavel Mazánek
  • MUDr. Tomáš Merta
  • MUDr. Peter Múdry, Ph.D.
  • prof. MUDr. Marie Nováková, Ph.D.
  • Hana Novotná
  • MUDr. Kristýna Polášková
  • MUDr. Ondřej Rohleder
  • PharmDr. Lenka Součková, Ph.D.
  • Mgr. Martina Štorová
  • Mgr. Adam Svobodník
  • MUDr. Marie Ulrichová
  • MUDr. Klára Vejmělková
  • MUDr. Danica Zapletalová

Principal Investigator

prof. MUDr. Jaroslav Štěrba, Ph.D.
prof. MUDr. Jaroslav Štěrba, Ph.D.
Principal Investigator

Assistant

Bc. Lucie Faberová, MSc
Bc. Lucie Faberová, MSc
Assistant